ESTRO 2024 - Abstract Book

S44 ESTRO 2024 The ESTRO POP-ART-1 study found that 71% of users wished to implement real-time radiation therapy. This desire contrasts with the AAPM Task Group 324 survey that found that 85% of sites most commonly use internal target volume, breath hold or abdominal compression for their treatments. This presentation will describe the benefits and challenges of hypofractionation, the impact of technology on clinically meaningful accuracy measurements, i.e. the dose delivered to the dynamic patient, and future image guidance and adaptive radiation therapy technology trends to further improve patient outcomes. Invited Speaker

3352

Image-guidance: Minimal vs going "all in"

Alison C Tree

The Royal Marsden NHS Foundation Trust, Radiotherapy, Sutton, United Kingdom. The Institute of Cancer Research, Radiotherapy, Sutton, United Kingdom

Abstract:

This talk will discuss why daily image-guidance is needed for prostate cancer, and describe the various methods of delivering this, covering fiducials, cone beam CT, MRI guidance and others. What is the minimum standard for prostate IGRT in 2024 and what are the “Bronze, Silver and Gold medals” for IGRT accuracy? Finally, we will discuss whether in the future image-guidance can yet still improve.

3353

Image-guided particle therapy: Did we close the gap?

Petra Trnkova

Medical University of Vienna, Department of Radiation Oncology, Vienna, Austria

Abstract:

Imaging plays a vital role in every workflow step of particle therapy. Due to the finite range of charged particles, leading to a higher sensitivity to uncertainties, an accurate image-guidance is even more critical than in photon radiotherapy. To be able to answer the question, whether the gap in image-guided particle therapy (IGPT) was closed, it is important to understand how the optimal IGPT should look like and analyse whether it has already been translated into the clinical environment. Innumerable research groups over the years have worked on wide range of research questions addressing different parts of IGPT: treatment planning, patient positioning, treatment adaptation, motion management and in-vivo verification. Their focus varied from a simple translation of the technology used in photon radiotherapy, over reduction of uncertainties, up to development of innovative approaches. Considering the clinical implementation, the pioneering institutes used often in-house developments leading to site-specific IGPT strategies. With growing number of particle therapy centres worldwide, commercial products became widely available resulting in higher